Publications - Papers
Use of Continuous ECG for Improvements in Assessing the Standing Response as a Positive Control for QT Prolongation
Anthony A. Fossa, Meijian Zhou, Nuala Brennan, Patrick Round and John Ford.
Said El-Haou, John Ford and James Milnes.
Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation
Simone Loose, Judith Mueller, Erich Wettwer, Michael Knaut, John Ford, James Milnes and Ursula Ravens.
Human Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial-Selective Kv1.5/IKur Inhibitor
Ford J., Milnes J., Wettwer E.,Christ T., Rogers M., Sutton K., Madge D., Virag L., Jost N., Horvath Z., Matschke K., Varro A,. Ravens, U.
The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation
John Ford, James Milnes, Said El Haou, Erich Wettwer, Simone Loose, Klaus Matschke, Benoit Tyl, Patrick Round, Ursula Ravens.
Atrial-like cardiomyocytes from human pluripotentstem cells are a robust preclinical model for assessing atrial-selective pharmacology
Harsha D Devalla.
The role of sodium channels in neuropathic pain. Seminars in Cell and Developmental Biology 17(5) 571-581
Rogers M., Tang L., Madge, D. and Stevens E.
An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects: British J Clinical Pharmacology 72 (6): 921–931
Patrick Round, Anthony Priestley and Jan Robinson.
Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor
Ford J., Milnes J., Wettwer E., Christ T., Rogers M., Sutton K., Madge D., Virag L., Jost N., Horvath Z., Matschke K., Varro A., and Ravens U
Carbon-14 radiosynthesis of 4-(5-chloro- 2-hydroxyphenyl)-3-(2-hydroxyethyl)-6- (trifluoromethyl)-[4-14C]quinolin-2(1H)-one (XEN-D0401), A novel BK channel activator
Sean L. Kitson, Stuart Jones, William Watters, Fiona Chan and David Madge, (2010): Labelled Compounds and Radiopharmaceuticals
Malik M., Hnatkova K., Ford J. and Madge D. (2008): Journal of Clinical Pharmacology; 48, 1146-1157
New Drugs Targeting the Cardiac Ultra-Rapid Delayed-Rectifier Current (IKur): Rationale, Pharmacology and Evidence for Potential Therapeutic Value
Ford JW., Milnes JT., : J Cardiovasc Pharmacol; 52, 105-120
Willett P., Wilton D., Hartzoulakis B., Tang R., Ford J.and Madge D., : J Chem. Inf. Model; 47, 1961-1966.
Identification of Selective Inhibitors of the Potassium Channel Kv1.1–1.2(3) by High-Throughput Virtual Screening and Automated Patch Clamp. Chem Med Chem 7 (10):1775-1783.
Soeren J. Wacker, Wiktor Jurkowski, Katie J. Simmons, Colin W. G. Fishwick, A. Peter Johnson, David Madge, Erik Lindahl, Jean-Francois Rolland, and Bert L. de Groot
Publications - Posters
A selective inhibitor of Kv1.1-(1.2)3 concatamer channels identified by high throughput virtual screening and automated patch clamp is effective in an ex vivo model of axonal demyelination. Ion Channels in Health and Disease: a symposium to celebrate the 50th anniversary of the Nobel Prize awarded to Alan Hodgkin and Andrew Huxley, Cambridge University, UK, Sept 16-17th 2013.
Biophysical characterization of duloxetine activity on voltage-gated sodium channels involved in pain transmission
Development of a hKv1.3 ion channel screening assay using the QPatch 16 automated patch-clamp platform
The Atrial Antiarrhythmic Drug XEN-D0101 Selectively Inhibits the Human Ultra-Rapid Delayed-Rectifier Potassium Current (IKur) Over Other Cardiac Ion Channels
Targeting the hKv1.3 potassium channel in the development of novel treatments for autoimmune diseases
State-Dependent Inhibitors of the Nav1.3 Sodium Channel for Treating Neuropathic Pain
Targeting the Nav1.3 Sodium Channel in the Development of Novel Treatments for Neuropathic Pain
A comparison of the effects of known Ion Channel Modulators against A K+ current recorded using autopatch & ‘conventional’ Ion Channel Screening technologies